Letter to the Editor
Pediatric patients with immune-mediated diseases on immunosuppressants have low risk of severe COVID-19 and no increase in flare rate after SARS CoV-2 exposure Author links open overlay panel Alexis Virgil Cochino a b ,
Oana Maria Farkas b ,
Andreea Ioan b Show more
Highlights
• Pediatric patients on immunosuppressive drugs had mild COVID-19.
• Risk of flare related to SARS CoV-2 exposure in rheumatic disease patients was similar to baseline.
• Seroprevalence survey identified high asymptomatic infection rate.
Recommended articles
Data for reference
The datasets generated and/or analyzed during the current study are available from the corresponding author upon reasonable request.
View Abstract © 2022 The British Infection Association. Published by Elsevier Ltd. All rights reserved.